BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/6/2016 5:24:00 PM | Browse: 1296 | Download: 2261
 |
Received |
|
2016-07-22 10:03 |
|
Peer-Review Started |
|
2016-07-25 12:11 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2016-09-20 13:14 |
|
Revised |
|
2016-10-01 00:48 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2016-10-21 18:17 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2016-10-27 17:22 |
|
Articles in Press |
|
2016-10-27 17:22 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-11-21 16:37 |
|
Publish the Manuscript Online |
|
2016-12-06 17:24 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Esperance AK Schaefer, James Meixiong, Christina Mark, Amy Deik, Daniel L Motola, Dahlene Fusco, Andrew Yang, Cynthia Brisac, Shadi Salloum, Wenyu Lin, Clary B Clish, Lee F Peng and Raymond T Chung |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| United States National Institutes of Health |
DK097855 |
| United States National Institutes of Health |
DK008191 |
| United States National Institutes of Health |
DK088951 |
| United States National Institutes of Health |
DK078772 |
|
| Corresponding Author |
Lee F Peng, Associate Medical Director of Liver Transplantation, Associate Professor of Medicine, Temple University Health System, 3509 N. Broad St., 9th Floor, Philadelphia, PA 19140, United States. lee.peng@tuhs.temple.edu |
| Key Words |
Apolipoprotein; Lipid; Hepatitis C virus; Gene silencing; Viral replication |
| Core Tip |
Hepatitis C virus (HCV) circulates as a very-low-density lipoprotein (VLDL)-like lipoviral particle. Apolipoprotein B100 (apoB100) is the core protein of VLDL, buts its role in HCV has remained incompletely characterized. Use of gene-editing with transcription activator-like effector nucleases permits the characterization of the role of apoB100 in HCV. We demonstrate that apoB100 is required for HCV infection. Loss of apoB100 results in the secretion of HCV virions with an altered lipid composition and limited ability to infect naive cells. Mipomersen, an FDA-approved antisense inhibitor of apoB100, has an anti-HCV effect and limits the viral infectivity.
|
| Publish Date |
2016-12-06 17:24 |
| Citation |
Schaefer EAK, Meixiong J, Mark C, Deik A, Motola DL, Fusco D, Yang A, Brisac C, Salloum S, Lin W, Clish CB, Peng LF, Chung RT. Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C. World J Gastroenterol 2016; 22(45): 9954-9965
|
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i45/9954.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i45.9954 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
